How "benign" is cutaneous mastocytosis? A Danish registry-based matched cohort study.
Comorbidity-adjusted analyses
Danish National Patient Registry
Epidemiology
Mastocytosis
Survival analyses
Journal
International journal of women's dermatology
ISSN: 2352-6475
Titre abrégé: Int J Womens Dermatol
Pays: United States
ID NLM: 101654170
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
11
02
2020
revised:
16
05
2020
accepted:
22
05
2020
entrez:
5
10
2020
pubmed:
6
10
2020
medline:
6
10
2020
Statut:
epublish
Résumé
There are limited estimates of the incidence rates (IRs) of mastocytosis, and only a few studies have addressed the long-term consequences of living with these diagnoses. Previous reports have shown that systemic mastocytosis is associated with leukemic transformations and an increased risk of death as opposed to cutaneous mastocytosis (CM) and indolent systemic mastocytosis (ISM), which have benign diagnoses with life expectancy rates similar to those of the background population. This study aimed to analyze the incidence and mortality of mastocytosis. A population-based matched cohort study of patients with mastocytosis between 1 January 1, 1977 and 31 December 31, 2014 was identified from the Danish National Health Registries. IRs of CM, ISM, and pediatric mastocytosis were highlighted. Survival estimates were compared with those of a healthy background population, using a Cox proportional hazard model. A total of 1461 patients with mastocytosis were identified. The annual IR of overall mastocytosis was 1.1 per 100,000 person years (95% confidence interval [CI], 1.0-1.2). Among children, the IR was 1.8 per 100,000 person years (95% CI, 1.6-2.1). The prevalence of any comorbidity was twice as high among patients with mastocytosis compared with the population without mastocytosis (odds ratio: 2.1; 95% CI, 1.8-2.5). The Charlson Comorbidity Index-adjusted mortality among adult patients with mastocytosis was HR Based on an entire nation, with free health care at the point of access, we estimated an annual IR of mastocytosis and its subgroups. We discovered that patients with ISM had an increased risk of death compared with the general population. Our data supported the overall benign nature of CM diagnosed after age 2 years.
Sections du résumé
BACKGROUND
BACKGROUND
There are limited estimates of the incidence rates (IRs) of mastocytosis, and only a few studies have addressed the long-term consequences of living with these diagnoses. Previous reports have shown that systemic mastocytosis is associated with leukemic transformations and an increased risk of death as opposed to cutaneous mastocytosis (CM) and indolent systemic mastocytosis (ISM), which have benign diagnoses with life expectancy rates similar to those of the background population.
OBJECTIVE
OBJECTIVE
This study aimed to analyze the incidence and mortality of mastocytosis.
METHODS
METHODS
A population-based matched cohort study of patients with mastocytosis between 1 January 1, 1977 and 31 December 31, 2014 was identified from the Danish National Health Registries. IRs of CM, ISM, and pediatric mastocytosis were highlighted. Survival estimates were compared with those of a healthy background population, using a Cox proportional hazard model.
RESULTS
RESULTS
A total of 1461 patients with mastocytosis were identified. The annual IR of overall mastocytosis was 1.1 per 100,000 person years (95% confidence interval [CI], 1.0-1.2). Among children, the IR was 1.8 per 100,000 person years (95% CI, 1.6-2.1). The prevalence of any comorbidity was twice as high among patients with mastocytosis compared with the population without mastocytosis (odds ratio: 2.1; 95% CI, 1.8-2.5). The Charlson Comorbidity Index-adjusted mortality among adult patients with mastocytosis was HR
CONCLUSION
CONCLUSIONS
Based on an entire nation, with free health care at the point of access, we estimated an annual IR of mastocytosis and its subgroups. We discovered that patients with ISM had an increased risk of death compared with the general population. Our data supported the overall benign nature of CM diagnosed after age 2 years.
Identifiants
pubmed: 33015290
doi: 10.1016/j.ijwd.2020.05.013
pii: S2352-6475(20)30096-4
pmc: PMC7522902
doi:
Types de publication
Journal Article
Langues
eng
Pagination
294-300Informations de copyright
© 2020 The Authors.
Références
J Allergy Clin Immunol. 2013 May;131(5):1429-31.e1
pubmed: 23219169
Epidemiology. 2007 Nov;18(6):805-35
pubmed: 18049195
J Invest Dermatol. 2010 Mar;130(3):804-15
pubmed: 19865100
Isr Med Assoc J. 2005 May;7(5):320-2
pubmed: 15909466
Curr Opin Hematol. 2010 Mar;17(2):125-32
pubmed: 20075725
Am J Hematol. 2016 Nov;91(11):1069-1075
pubmed: 27428296
Blood. 2017 Mar 16;129(11):1420-1427
pubmed: 28031180
J Allergy Clin Immunol. 2009 Sep;124(3):514-21
pubmed: 19541349
Am J Hematol. 2015 Mar;90(3):250-62
pubmed: 25688753
Scand J Public Health. 2011 Jul;39(7 Suppl):72-4
pubmed: 21775357
Leuk Res. 2001 Jul;25(7):603-25
pubmed: 11377686
Br J Dermatol. 2016 Feb;174(2):411-3
pubmed: 26138896
Br J Haematol. 2014 Aug;166(4):521-8
pubmed: 24761987
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
Immunol Allergy Clin North Am. 2014 May;34(2):283-95
pubmed: 24745674
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Eur J Clin Invest. 2007 Jun;37(6):435-53
pubmed: 17537151
Z Evid Fortbild Qual Gesundhwes. 2016 Oct;115-116:33-48
pubmed: 27837958
N Engl J Med. 2007 Dec 20;357(25):2616-23
pubmed: 18094382
Br J Dermatol. 2015 Mar;172(3):642-51
pubmed: 25662299
Allergy. 2009 Oct;64(10):1427-43
pubmed: 19772513
J Eur Acad Dermatol Venereol. 2013 Jan;27(1):97-102
pubmed: 22126331
Eur J Epidemiol. 2014 Aug;29(8):541-9
pubmed: 24965263
Dermatol Online J. 2011 Mar 15;17(3):7
pubmed: 21426873
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254